TO REGISTER, VISIT WWW.THECONFERENCEFORUM.ORG OR CALL 646-350-2580 Large Pharma/Biotech Evaluation & Partnering Panel Boehringer Ingelheim ● Biogen Idec ● Johnson & Johnson Hospira ● Pfizer ● Ranbaxy Labs ● Roche ● Vertex How Delivery is Changing the Therapeutic Landscape Alcyone Lifesciences ● Alnylam ● Medtronic Shire HGT ● US CEEDD, GSK Developing & Commercializing Early Stage Technologies from Academia BioPontis ● Enlight BioSciences ● GSK Pfizer ● UC Santa Barbara Strategies for Developing and Commercializing Biobetters & Biosimilars Momenta Pharmaceuticals ● Shire HGT STC Biologics Drug Delivery Business Models: The View from Wall Street SROne ● Thomas McNerney & Partners Track One - Drug Delivery Formulation Technologies Company presentations on formulation technologies that can enhance, enable, or facilitate delivery of a drug. Track Two - Drug Delivery Device Technologies Company presentations on needle-free delivery devices, auto injectors, pen injectors, powder injection devices, microneedle systems, inhalation devices, nasal delivery devices, non-biodegradable implants or similar, transdermal patches, patch pumps and other wearable drug administration systems, etc. 2012 CONFERENCE HIGHLIGHTS DRUG DELIVERY PRESENTATIONS Keynote Speaker Robert Langer, PhD David H. Koch Institute Professor MIT Chair Barbara Lueckel, PhD Global Business Development Director Roche Device Keynote Speaker Stephen N. Oesterle, MD Senior Vice President for Medicine and Technology Medtronic Organized by Executive Sponsors
9
Embed
2012 CONFERENCE HIGHLIGHTS DRUG DELIVERY PRESENTATIONS · 10/1/2012 · Company presentations on formulation technologies that can enhance, enable, or facilitate delivery of a drug.
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
TO REGISTER, VISIT WWW.THECONFERENCEFORUM.ORG OR CALL 646-350-2580
Large Pharma/Biotech Evaluation & Partnering PanelBoehringer Ingelheim ● Biogen Idec ● Johnson & Johnson Hospira ● Pfizer ● Ranbaxy Labs ● Roche ● Vertex
How Delivery is Changing the Therapeutic LandscapeAlcyone Lifesciences ● Alnylam ● MedtronicShire HGT ● US CEEDD, GSK
Developing & Commercializing Early Stage Technologies from AcademiaBioPontis ● Enlight BioSciences ● GSKPfizer ● UC Santa Barbara
Strategies for Developing and Commercializing Biobetters & BiosimilarsMomenta Pharmaceuticals ● Shire HGT STC Biologics
Drug Delivery Business Models: The View from Wall StreetSROne ● Thomas McNerney & Partners
Track One - Drug Delivery Formulation Technologies Company presentations on formulation technologies that can enhance, enable, or facilitate delivery of a drug.
Track Two - Drug Delivery Device Technologies Company presentations on needle-free delivery devices, auto injectors, pen injectors, powder injection devices, microneedle systems, inhalation devices, nasal delivery devices, non-biodegradable implants or similar, transdermal patches, patch pumps and other wearable drug administration systems, etc.
2012 CONFERENCE HIGHLIGHTS DRUG DELIVERY PRESENTATIONS
Keynote Speaker
Robert Langer, PhDDavid H. Koch
Institute ProfessorMIT
Chair
Barbara Lueckel, PhDGlobal Business
Development DirectorRoche
Device Keynote Speaker
Stephen N. Oesterle, MDSenior Vice President for Medicine and Technology
TO REGISTER, VISIT WWW.THECONFERENCEFORUM.ORG OR CALL 646-350-2580
Dear Life Science Executive,
The Conference Forum is delighted to present the 2nd Annual PODD, Partnership Opportunities in Drug Delivery. This event is designed with three purposes:
1. To present a strategic level program for pharma and biotech business development and external licensing professionals with a thorough overview of the latest drug delivery technologies available along with an update on deals and opportunities to enhance patients’ quality of life, improve therapies and extend the life cycle of a drug.
2. To provide drug delivery and specialty pharma companies with a platform to present their technologies and get the latest insights from established pharma and biotechs as well as emerging companies on what the delivery and formulation needs are.
3. To offer ample networking time, facilities and services for one-on-one meetings to establish new business contacts and enhance existing ones.
The ultimate goal for PODD is to foster a meeting place that inspires innovation and advancement of drug development and delivery as well as providing support for the leaders behind the movement.
Sincerely,
Michelle McDermott Valerie BowlingConference Producer Executive Director
TO REGISTER, VISIT WWW.THECONFERENCEFORUM.ORG OR CALL 646-350-2580
8:00 amBreakfast and Registration
8:30 amChair’s Opening RemarksBarbara Lueckel, PhDGlobal Business Development Director, Roche
8:45 amOpening Keynote Address: The Future of Drug DeliveryRobert Langer, PhDDavid H. Koch Institute Professor, MIT
At the inaugural 2011 event, Dr Langer gave a wonderful presentation on drug delivery technologies and opportunities. For the 2012 event, Dr Langer will share his insights into the future of drug delivery.
Dr. Langer is a widely recognized and cited researcher in biotechnology, especially in the fields of drug delivery systems and tissue engineering. He operates the world’s largest biomedical engineering lab in the world and is a prolific inventor with approximately 790 issued and pending patents worldwide.
Dr. Langer’s patents have been licensed or sublicensed to over 220 pharmaceutical, chemical, biotechnology and medical device companies; a number of these companies were launched on the basis of these patent licenses.
Among the products which have stemmed from his research: a long acting growth hormone formulation that prevents dwarfism in children; the PreludeTM SkinPrep system for needle-free drug delivery and analyte extraction; and the Gliadel Wafer, the first therapy to extend the lives of patients with glioblastoma multiforme brain cancer. Dr. Langer has co-founded multiple companies including MicroCHIPS, Momenta Pharmaceuticals, TransForm Pharmaceuticals, Pervasis Therapeutics, Arsenal Medical, and Selecta Biosciences, and sits on the Board of more than twenty companies including Alkermes, Cerulean Pharma, Kala Pharmaceuticals, and Humacyte.
9:45 amHow Biotech and Pharma Currently View Drug Delivery Technologies: Evaluation & Partnering
• What are the key delivery technologies of interest?
• Review of key therapeutic categories requiring DDS technology
• How companies are sourcing DDS technologies?
• What are the major hurdles in partnering with a DDS company?
• What are the keys to a successful pharma-DDS partnership?
Moderated by:
Barbara Lueckel, PhD, Global Business Development Director, Roche
Panelists:
Jessica Ballinger, Senior Director, Protein Formulation Development, Biogen Idec
Weiguo Dai, PhD, Scientific Director, Janssen Fellow, Johnson and Johnson
Mary Gardner, Director, Technology Assessment, Hospira
Keith Horspool, PhD, VP Pharmaceutical Development, Boehringer Ingelheim
Julia Rashba-Step, PhD, Senior Director, Novel Delivery Technologies, Pfizer
10:30 amNetworking Break and Partnering Hour (Partnering Service Desk Opens)
11:30 amThe DDS Company Viewpoint on Partnering
In this collaborative voice of drug delivery companies, we get a solid understanding of the obstacles and challenges they face in executing and managing a successful partnership.
• What DDS companies are looking for in a partner
• Challenges of partnering with big pharma
• Types of collaborations and deal terms
• Keys to successful partnerships
Moderated by:
Barbara Lueckel, PhD, Global Business Development Director, Roche
Panelists:
Andrea Leone-Bay, Vice President Pharmaceutical Development, Mannkind
Jonathan Rigby, President & CEO, SteadyMed Therapeutics
Anne Roush, Business Development Manager, 3M Drug Delivery Systems Division
PODD: PARTNERSHIP OPPORTUNITIES IN DRUG DELIVERY AGENDA
TO REGISTER, VISIT WWW.THECONFERENCEFORUM.ORG OR CALL 646-350-2580
12:15 pmStrategies for Developing and Commercializing Biobetters & Biosimilars
In this panel, we explore the development strategies and role of drug delivery to differentiate biosimilars. What you must know and understand about opportunities in this area is central to the discussion along with the following:
Jim Roach MD, Senior Vice President, Development & CMO, Momenta Pharmaceuticals, Inc.
Barbara Rosengren, Vice President, Strategic Product Development, Momenta Pharmaceuticals, Inc.
12:45 pmAn Unbiased Approach to Drug Development Technologies
In this presentation, our presenter discusses options for drug development technologies including parallel drug formulation screening and formulation technology use to increase bioavailability class II and IV products.
Anil Kane, PhD, MBA, Executive Director, Global Science & Technology, Pharmaceutical Development Services, Patheon
1:00 pmLuncheon and Partnering Meetings
AGENDA PODD: PARTNERSHIP OPPORTUNITIES IN DRUG DELIVERY
Track One - Drug Delivery Formulation TechnologiesChaired by: Avinash Thombre, PhD, Research Fellow, Pfizer Global R&DApproximately 12-14 companies present formulation technologies that can enhance, enable, or facilitate delivery of a drug. Examples: nanoparticles, polymers/biodegradable materials, liposomes, tablets/capsules/liquids, conjugates, microparticles, lipids/emulsions, excipients, orally-disintegrating tablets/films, etc.
Presenting Companies:AptalisGrace/Formac PharmaceuticalsGSKOctoplusDLVR TherapeuticsConvoy TherapeuticsEnduRXCIMAHovioneMedincellXeris PharmaceuticalsCeruleanEndo Health SolutionsUnigene Laboratories
Track Two - Drug Delivery Device TechnologiesChaired by: Philip Green, PhD, Senior Director, Drug Delivery Devices, Merck Bioventures, Merck Research LaboratoriesApproximately 12-14 companies present needle-free delivery devices, auto injectors, pen injectors, powder injection devices, microneedle systems, inhalation devices, nasal delivery devices, non-biodegradable implants or similar, transdermal patches, patch pumps and other wearable drug administration systems, etc.
TO REGISTER, VISIT WWW.THECONFERENCEFORUM.ORG OR CALL 646-350-2580
6:00 pmNetworking Reception
8:00 amBreakfast and Partnering Meetings
8:30 amChair’s Welcome
Barbara Lueckel, PhDGlobal Business Development Director, Roche
8:40 amFrom Enabling Delivery to Delivering Payor, Regulatory & Patient Outcomes: The New Imperative for Advanced Technologies
Developers of medicines face increasing expectations for improved outcomes - from payors, from regulators, and from patients. The role of advanced delivery technology providers must shift from ensuring achievement of the desired delivery profile to driving therapeutic benefits. This will require both developers and technologists to use different approaches, different partnerships, and different mindsets.
TO REGISTER, VISIT WWW.THECONFERENCEFORUM.ORG OR CALL 646-350-2580
2:00 pmDeveloping & Commercializing Early Stage Technologies from Academia
Some of the most exciting developments in drug delivery are coming from academia. This session is dedicated to helping you understand how to access early stage technologies and become involved with the development and ultimate commericalization of such technologies.
• Types of partnering models, beyond straight licensing and sponsored research; examples of recent deals resulting in DDS start-ups
• Opportunities and challenges: reproducibility; tech transfer/license challenges; balance between investor and PI/institution needs; examples of what is working
• Intellectual property issues: assignments, conflict of interest, shared interests, research collaborations, working with 3rd parties, solutions to address (e.g. incubators)
Richard A. Basile, CEO & Principal, BioPontis Alliance
Kevin Bitterman, PhD, Board Member, Kala Pharmaceuticals and Principal, Polaris Venture Partners
Samir Mitragotri, PhD, Professor of Chemical Engineering, UC Santa Barbara
Ron Newbold, Head - Strategic Research Partnerships, External R&D Innovation, Worldwide Research & Development, Pfizer
A. Lee Shorter, PhD, Director, Disruptive Technology Seeker, GSK
2:45 pmDrug Delivery Business Models: The View from Wall St.
• What does Wall St. think of drug delivery in general?
• How have business models evolved over the years?
• Which business models are in and out of favor at the moment?
• Tips on raising Wall Street funds for your company
• A few guesses at the future
David Philips, Managing Partner, SROne
Alex Zisson, Partner, Thomas McNerney & Partners
3:30 pm Opportunities in Pediatrics and Geriatrics
Utilizing the examples of geriatrics and pediatrics, we explore unmet needs of specific patient populations and how drug delivery technologies can play a significant role. More specifically:
• Formulation needs and challenges related to drug delivery for pediatrics and geriatrics
• Delivery technologies available to meet these special needs
• Key pediatric and geriatric therapeutic indications requiring novel DDS
• Examples of partnering opportunities – drug delivery platform technologies, specific drug formulations
• Regulatory hurdles for gaining approval of patient-centric formulations
Panelists:
Moji Adeyeye, PhD, President & Chief Scientist, Elim Pediatric Pharmaceuticals
Benoit Hebert, Ph.D., MBA, Vice President, Business Development & Licensing, Pediapharm, Inc.
Daniel E. Schaufelberger, PhD, Scientific Director, Pharmaceutical Development & Manufacturing Sciences, Pediatric Center of Excellence, Janssen R&D, LLC
Sven Stegemann, PhD, President, Geriatric Medicine Society
4:15 pmConference Concludes
AGENDA PODD: PARTNERSHIP OPPORTUNITIES IN DRUG DELIVERY
7
1:00 pmLuncheon Sessions
Attendees have a choice to be part of our open networking luncheon or join a round table discussion luncheon dedicated to a specific topic. Each of the topic round tables has a dedicated moderator with expertise in the particular area.
The Potential Impact of Disruptive Innovation for Pharma R&DModerator:A. Lee Shorter, PhD, Director, Disruptive Technology Seeker, GSK
Drug Delivery Systems for Emerging MarketsModerator:Avinash Thombre, PhD, Research Fellow, Pfizer Global R&D
Ocular Delivery of Protein TherapeuticsModerator:Patrick Hughes, PhD, Senior Director, Drug Delivery Sciences, Allergan
TO REGISTER, VISIT WWW.THECONFERENCEFORUM.ORG OR CALL 646-350-2580
The Boston Park Plaza Hotel50 Park Plaza at Arlington StreetBoston, MA 02116-3912Tel: 617-426-2000www.bostonparkplaza.com
The Boston Park Plaza Hotel & Towers is located only 3 miles from Logan International Airport and only 200 yards from Boston Common & the Public Garden. The hotel is easily accessible to shopping along world renowned Newbury Street, Faneuil Hall Marketplace, the Theatre & Financial Districts and most historic landmarks.
Book early and be sure to request the special “PODD” conference room rate.
Business Development
• External Licensing
• Technology Licensing
• Portfolio Management
• Research & Technology Development
• Pharmaceutical Formulation/Sciences
From Drug Delivery and Specialty Pharma:
• Business Development
• Licensing
• Marketing
• Formulation Sciences
• Technology Development
• Commercial Development
The Investment Community
The early bird conference fee of $1,895 covers all program sessions and includes breakfasts, lunches, reception, access to partnering services and conference documentation.
Discount ProgramsGroup Registration - Receive a 10% discount off each registration when two or more colleagues from the same company register.
Full time academicians and government employee rates available. Partial and full scholarships for start up biotechs available. Large group discount rates available.
Please contact us at [email protected] for discount rates and scholarships.
Two Ways to RegisterOnline - www.theconferenceforum.org
Telephone - 646-350-2580
Payment PolicyPayment must be received in full by the event date. All discounts will be applied to the Conference fee only (excluding add-ons), and cannot be combined with any other offer.
Substitution and Cancellation PolicyIf you are unable to attend and would like to register a substitute, please email us at [email protected]. If you need to cancel your registration, please note the following policies based on the start date of the event:
Ten or more business days prior: A full refund less the administration fee of $295, or a pass to another event valid for two years from the date of issue.
Less than ten business days prior: A pass to a future event for either yourself or a colleague from the same company valid for two years from the date of issue.
Do You Want To Reach the Audience at This Event? Share your expertise and showcase your product or services to key industry decision-makers. For information on sponsorship or exhibit opportunities, please contact our Sales Department at [email protected] or 646-350-2586. To get involved as a Press or Media partner, please contact Customer Service at [email protected] or call 646-350-2580 Ext 310.
8
PODD: PARTNERSHIP OPPORTUNITIES IN DRUG DELIVERY REGISTRATION